Management of Thyroid carcinoma: Hahnemann experience

Publish Year: 1380
نوع سند: مقاله ژورنالی
زبان: English
View: 74

متن کامل این Paper منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل Paper (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IRJNM-9-1_003

تاریخ نمایه سازی: 7 تیر 1401

Abstract:

The primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. The post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation (I-۱۳۱ Na), external beam radiation therapy (EBRT) and occasionally adjuvant chemotherapy. This retrospective study analyzes the managements of ۱۵۳ patients (۱۰۲, ۵۱), age range ۱۰-۹۶ years, mean age ۵۰.۲ years treated for thyroid carcinoma. The range of follow-up was ۱.۰-۲۹۴ months with median follow-up for ۶۰.۴ months. Twenty patients without therapy were excluded. Group A included ۸۷ patients treated with I-۱۳۱. Group B consisted of ۱۳ patients received EBRT. Group C included both therapies in ۳۳ patients. The therapies in all different stages of thyroid carcinoma and with various histopathologies were reviewed.

Authors

Simin Dadparvar

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA

John Lahaniatis

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA

Fariba Asrari

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA

Athar Shaikh

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA

Nasrin Ghesani

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA

Mark Tulchinsky

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA

Walter Slizofski

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA

Luther Brady

Division of Nuclear Medicine, Department of Radiation Oncology and Nuclear Medicine, Hahnemann University, Philadelphia, PA, USA